Polycystic liver disease

What is polycystic liver disease?

Polycystic liver disease (PLD) is a genetic condition where the liver develops multiple fluid-filled sacs, often more than ten cysts in people without a known family history. These cysts tend to increase in number and size over time, although the rate of progression varies considerably between individuals.

The disease occurs in two main genetic contexts:

• Autosomal dominant polycystic kidney disease (ADPKD): the most common form. It causes cysts to grow in both the kidneys and the liver. Up to 90% of people with this condition develop liver cysts over time.

• Autosomal dominant polycystic liver disease (ADPLD): a rarer type where cysts grow exclusively in the liver, leaving the kidneys unaffected, though it can cause more severe liver swelling.

Why severity matters: doctors grade PLD based on the total number of cysts and liver size. In severe cases, the liver can balloon drastically, causing severe abdominal pain, a feeling of fullness, and an impaired quality of life that may eventually require specialist interventions, including surgery or, in rare severe cases, liver transplantation.

Symptoms of polycystic liver disease

The majority of people with PLD, particularly those with few or small cysts, have no symptoms. Symptoms develop as total cyst volume increases and liver volume expands:

• Abdominal fullness, distension, or a visible increase in abdominal girth from massively enlarged liver

• Early satiety and nausea from gastric compression by the enlarged liver

• Right upper abdominal discomfort or pain, typically a persistent dull aching heaviness

• Shortness of breath from diaphragm elevation by a markedly enlarged liver

• Reduced mobility and difficulty bending forward in severe hepatomegaly

• Acute severe pain from cyst haemorrhage or cyst infection, both uncommon complications

• Back pain from the weight and displacement effects of a massively enlarged liver

• In severe cases: malnutrition from early satiety and gastric compression

Importantly, liver function is usually remarkably preserved even in severe PLD, as the numerous cysts replace liver volume without destroying functional hepatocytes to a clinically significant degree in most cases.

What causes polycystic liver disease?

PLD results from genetic mutations affecting biliary epithelial cell development and cyst fluid secretion. Contributing factors include:

• PKD1 and PKD2 gene mutations cause ADPKD with combined kidney and liver cyst formation. PKD1 mutations cause more severe and earlier-onset disease than PKD2 mutations.

• PRKCSH and SEC63 mutations cause isolated ADPLD through impaired protein folding in biliary epithelial cells, promoting cyst formation without kidney involvement.

• LRP5 mutations cause ADPLD with a distinct mechanism involving Wnt signalling pathway disruption in biliary epithelial cells.

• Female sex and oestrogen female sex is consistently associated with more severe PLD than male sex in ADPKD, and exogenous oestrogen from oral contraceptives and hormone replacement therapy accelerates cyst growth. Pregnancy is associated with significant cyst enlargement.

• Age cyst number and liver volume increase progressively with age in all forms of PLD.

• Family history PLD is autosomal dominant, meaning each child of an affected parent has a 50% chance of inheriting the causative mutation.

How is a polycystic liver disease detected?

PLD is detected through abdominal imaging, with blood tests assessing liver function and identifying any associated kidney involvement.

Abdominal MRI Elfcare’s full body MRI directly maps your liver and kidneys to provide the ultimate baseline for polycystic liver disease (PLD). It can identify multiple liver cysts, assess their distribution and overall liver size, and evaluate the kidneys for associated polycystic kidney disease. It can also identify large cysts or other findings that may require further specialist assessment.

Blood tests assess liver function, kidney function, and hormonal factors relevant to PLD progression. Relevant markers in Elfcare's panel include:

• ALT, AST, GGT, ALP, and bilirubin assess liver function. Liver function is typically well preserved in PLD even with significant liver enlargement, making abnormal liver enzymes an important signal of complications including cyst infection or biliary compression

• Albumin reflects liver synthetic function, typically normal in PLD until very advanced disease

• Creatinine, cystatin C, and eGFR assess kidney function, critically important when ADPKD is suspected or confirmed, as renal disease is the primary cause of morbidity and mortality in ADPKD

• Hormonal markers relevant to oestrogen-driven cyst growth, particularly in women considering or currently taking hormonal therapies

• CRP and full blood count elevated CRP and white cell count support cyst infection as a complication in a patient with known PLD presenting with fever and abdominal pain

• Haemoglobin anaemia can develop in advanced ADPKD from progressive renal impairment reducing erythropoietin production

Why early detection matters

Most PLD progresses slowly and never reaches a severity requiring intervention. But for the proportion with progressive disease, identifying PLD early allows for hormonal modification, specifically avoiding oestrogen-containing therapies that accelerate cyst growth, before significant liver volume has been lost to cysts. It also allows for family screening, identifying first-degree relatives who may have inherited the causative mutation and who benefit from their own monitoring programme. In ADPKD, early identification of renal involvement allows for nephroprotective management that significantly slows kidney function decline, a disease-modifying intervention with clear long-term benefit. Identifying severe PLD before malnutrition and functional decline have developed allows for timely specialist referral for surgical or transplantation assessment.

How Elfcare can help

Elfcare's full body MRI images both the liver and kidneys, helping identify liver cysts, assess overall disease extent, and evaluate for associated ADPKD. This provides the structural information needed to guide appropriate monitoring and specialist referral.

Our blood panel covers liver function, kidney function, and relevant hormonal markers, providing the functional context alongside the structural MRI findings.

If our MRI or blood tests identify polycystic liver disease or related findings, we take care of further diagnostics or refer you to the appropriate specialist.